All In Biotech

NDA 219745 · Accord

Camcevi Etm

Leuprolide Mesylate · Subcutaneous

Last checked: Nov 19, 2026Latest source record: Jul 21, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2025

Aug 25, 2025

Approved uses

1

Original approval plus efficacy supplements

Registered trials

457

123 Phase 3, 53 recruiting

FAERS reports

1,547

1,095 serious, 129 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 8, 2025.

1. INDICATIONS AND USAGE CAMCEVI ETM is indicated for the treatment of adult patients with advanced prostate cancer. CAMCEVI ETM is a gonadotropin-releasing hormone (GnRH) agonist indicated for the treatment of adult patients with advanced prostate cancer. ( 1 )

Mechanism: Leuprolide, a GnRH agonist, acts as an inhibitor of gonadotropin secretion. Animal and human studies indicate that following an initial stimulation of gonadotropins, chronic administration of leuprolide results in suppression of ovarian and testicular steroidogenesis. This effect is reversible upon discontinuation of drug therapy.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 25, 2025 Original approval · Type 5 - New Formulation or New Manufacturer LetterLabel
1 products under this application
  • CAMCEVI ETM · LEUPROLIDE MESYLATE EQ 21MG BASE · EMULSION, SUBCUTANEOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Leuprolide" as an intervention, any sponsor and status, largest first.

All 457 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective117
  • fatigue93
  • off label use90
  • nausea79
  • headache68
  • malignant neoplasm progression62
  • disease progression56
  • vomiting49
  • febrile neutropenia48
  • product storage error45
  • product use in unapproved indication41
  • anaemia39

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20052
20063
20116
20127
201327
201431
201531
201630
201762
201894
2019151
2020126
2021140
2022126
2023135
2024142
2025229
2026205

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 567 on PubMed

Sponsor: Accord

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.